Organon & Co. Declares Quarterly Dividend of $0.28 (NYSE:OGN)

Organon & Co. (NYSE:OGN - Get Free Report) declared a quarterly dividend on Thursday, February 13th,Wall Street Journal reports. Shareholders of record on Monday, February 24th will be paid a dividend of 0.28 per share on Thursday, March 13th. This represents a $1.12 annualized dividend and a yield of 7.27%. The ex-dividend date of this dividend is Monday, February 24th.

Organon & Co. has raised its dividend by an average of 26.0% per year over the last three years. Organon & Co. has a dividend payout ratio of 25.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Organon & Co. to earn $3.78 per share next year, which means the company should continue to be able to cover its $1.12 annual dividend with an expected future payout ratio of 29.6%.

Organon & Co. Price Performance

NYSE:OGN traded up $0.13 during trading hours on Tuesday, hitting $15.41. The stock had a trading volume of 949,779 shares, compared to its average volume of 2,760,587. The company has a 50 day simple moving average of $15.35 and a two-hundred day simple moving average of $17.38. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The firm has a market capitalization of $3.97 billion, a price-to-earnings ratio of 3.07, a P/E/G ratio of 0.83 and a beta of 0.76.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Research analysts forecast that Organon & Co. will post 3.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OGN shares. Morgan Stanley decreased their target price on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a research report on Friday. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Barclays decreased their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.